Efgartigimod alfa/Hyaluronidase

艾加莫德α/透明质酸酶

Report date: 2026/02/24 16:34:53

Base Information

Drug NameEfgartigimod alfa/Hyaluronidase
Drug Alias NameEfgartigimod alfa/Hyaluronidase-QVFCefgartigimod alfa and hyaluronidase-qvfcVYVGART HYTRULOVYVDURA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonistsHyaluronic acid modulators
TargetsIgG receptor FcRn large subunit p51Hyaluronic acid
Therapy Area/IndicationsAnti-synthetase SyndromePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingPolyradiculoneuropathy +[8] 
Global Approved IndicationsPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingMyasthenia Gravis
Approved Indications in ChinaPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Original Approved Country/TerritoryUnited States
Original Approved Date2023/06/20
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsYes Efgartigimod alfa
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArgenx BV
China Registration ClassN/A

Develop Information

Active CompaniesArgenx SeZai Lab LtdArgenx BV
Inactive CompaniesN/A
Active IndicationsAnti-synthetase SyndromePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingPolyradiculoneuropathy +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A